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Peripheral T-cell lymphomas are very aggressive hematologic malignancies for which there is no targeted therapy.
New, rational approaches are necessary to improve the very poor outcome in these patients. Phosphatidylinositol-
3-kinase is one of the most important pathways in cell survival and proliferation. We hypothesized that phos-
phatidylinositol-3-kinase inhibitors could be rationally selected drugs for treating peripheral T-cell lymphomas.
Several phosphatidylinositol-3-kinase isoforms were inhibited genetically (using small interfering RNA) and phar-
macologically (with CAL-101 and GDC-0941 compounds) in a panel of six peripheral and cutaneous T-cell lym-
phoma cell lines. Cell viability was measured by intracellular ATP content; apoptosis and cell cycle changes were
checked by flow cytometry. Pharmacodynamic biomarkers were assessed by western blot. The PIK3CD gene,
which encodes the δ isoform of phosphatidylinositol-3-kinase, was overexpressed in cell lines and primary sam-
ples, and correlated with survival pathways. However, neither genetic nor specific pharmacological inhibition of
phosphatidylinositol-3-kinase δ affected cell survival. In contrast, the pan-phosphatidylinositol-3-kinase inhibitor
GDC-0941 arrested all T-cell lymphoma cell lines in the G1 phase and induced apoptosis in a subset of them. We
identified phospho-GSK3b and phospho-p70S6K as potential biomarkers of phosphatidylinositol-3-kinase
inhibitors. Interestingly, an increase in ERK phosphorylation was observed in some GDC-0941-treated T-cell lym-
phoma cell lines, suggesting the presence of a combination of phosphatidylinositol-3-kinase and MEK inhibitors.
A highly synergistic effect was found between the two inhibitors, with the combination enhancing cell cycle arrest
at G0/G1 in all T-cell lymphoma cell lines, and reducing cell viability in primary tumor T cells ex vivo. These results
suggest that the combined treatment of pan-phosphatidylinositol-3-kinase + MEK inhibitors could be more effec-
tive than single phosphatidylinositol-3-kinase inhibitor treatment, and therefore, that this combination could be
of therapeutic value for treating peripheral and cutaneous T-cell lymphomas.
©2013 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2012.068510
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ABSTRACT
Introduction
Peripheral T-cell lymphomas (PTCL) are a heterogeneous
group of disorders with a very low incidence and very poor
prognosis.1,2 The molecular biology of PTCL is poorly under-
stood, partially due to the rarity of the disease, the hetero-
geneity of subtypes and the low number of appropriate mod-
els (no representative cell lines are available and no current
mouse model recapitulates the human disease). These
restrictions have limited understanding of the pathogenesis
of PTCL and, therefore, the development of the new targeted
therapies that are necessary to improve the outcome of
patients with this disease.3
The phosphatidylinositol-3-kinase (PI3K) family of proteins
participates in one of the most essential pathways for cell sur-
vival, proliferation and growth. It is an important mediator of
drug resistance and it has been described to be frequently
altered in a wide variety of types of human cancer.4-6 Two sub-
classes of PI3K have been related to cancer: class IA (p110a, b
and δ isoforms of the catalytic subunit) is predominantly acti-
vated by tyrosine kinases, and class IB (p110γ isoform) is
mainly activated by G-protein-coupled receptors. Upon
extracellular stimulation, PI3K phosphorylate phos-
phatidylinositol 4,5 biphosphate (PIP2) to form phos-
phatidylinositol 3,4,5 triphosphate (PIP3). Subsequently,
PIP3 can phosphorylate AKT, which initiates a signaling
cascade of protein phosphorylation leading to cell survival,
growth and proliferation. The activity of PI3K can be inhib-
ited by the phosphatase and tensin homologue (PTEN),
which acts as a tumor suppressor protein.4-6
Since aberrant regulation of the PI3K pathway has been
frequently observed in leukemic cells (presumably due to
activating signals from the microenvironment rather than
mutations in genes belonging to the pathway), PI3K is con-
sidered to be a promising target for therapy.4,6,7 Preclinical
experiments indicated that the PI3K inhibitors (PI3Ki)
LY294002 and wortmannin induced apoptosis in leukemic
cells, but they were also toxic to normal cells, probably
because of the low specificity and inhibition of other kinas-
es. Recently, selective isoform-specific inhibitors, such as
the PI3Kδ inhibitor CAL-101, have appeared to affect sur-
vival of chronic lymphocytic leukemia cells and CAL-101
has entered phase I/II clinical trials. Although the single
specificity inhibitors are effective in vitro, their effect in
patients appears to be modest. Therefore, combination
therapy targeting different intermediates of the PI3K signal-
ing pathway is also under investigation. Furthermore, since
lymphomagenesis involves aberrant regulation of various
signal transduction pathways, simultaneous inhibition of
multiple deregulated targets is considered to be a promising
therapeutic strategy.4
The aims of this study were to determine the efficiency
of PI3K inhibition in PTCL, to look for pharmacodynamic
biomarkers, and to identify markers that could distinguish
responders from non-responders.
Design and Methods
The molecular signature and bioinformatic analysis 
of peripheral T-cell lymphoma
The PTCL molecular signature was identified by comparing the
gene expression profile in a series of 38 frozen PTCL cases and six
reactive lymph nodes, and further analyzed using Connectivity
Map (Cmap)8 and Gene Set Enrichment Analysis (GSEA)9 pro-
grams, as described in the Online Supplementary Design and
Methods. All microarray data are available at the Gene Expression
Omnibus under accession number GSE36172. The research was
approved by the ethical committees of the Instituto de Salud
Carlos III (Madrid, Spain) and the Hospital Universitario Marqués
de Valdecilla (Santander, Spain).
Cell lines, primary samples and reagents
The cell lines and primary samples are described in the Online
Supplementary Design and Methods. GDC-0941 was obtained from
Chemdea (Ridgewood, NJ, USA). LY294002 and UO126 were pur-
chased from Calbiochem (Darmstadt, Germany). CAL-101 was
obtained from Selleck Chemicals (Houston, TX, USA). ETP-45658
was developed10 and kindly provided by the Experimental
Therapeutics Program of the Spanish National Cancer Research
Center (Madrid, Spain).
PIK3CD and PIK3CA genetic silencing
MyLa, SR786 and HuT78 cell lines were electroporated with
specific small interfering RNA (siRNA) against the PIK3CD and
PIK3CA genes, using the Neon® Transfection System (Invitrogen,
Carlsbad, CA, USA), as described in the Online Supplementary
Design and Methods.
Pharmacological inhibition assays
For drug cytotoxicity experiments, cell lines and primary tumor
T cells were treated for 72 or 48 h, respectively, with PI3Ki, MEK
inhibitors (MEKi) or their combinations. Cell viability was meas-
ured as the intracellular ATP content using the CellTiter-Glo
Luminescent Cell Viability Assay (Promega, Madison, WI, USA)
following the manufacturer’s instructions. For drug combination
experiments, the combination index (CI) was calculated according
to the method of Chou and Talalay.11 The distribution of cells
among different phases of the cell cycle and induction of apoptosis
were evaluated by flow cytometry, as described in the Online
Supplementary Design and Methods. All experiments were done in
triplicate and all numerical data are expressed as the average of the
values ± the standard error of the mean (SEM). 
Results
Phosphatidylinositol-3-kinase as a potential 
therapeutic target in peripheral T-cell lymphoma
In order to test drugs that could be of therapeutic value in
PTCL, we used the Cmap program and a PTCL molecular
signature generated in our group of 38 PTCL cases and in
six reactive lymph nodes. Cmap identified two
PI3K/mTOR pathway inhibitors among the drugs that
could most significantly reverse this PTCL signature (Figure
1A). We note that trichostatin A and MS-275, two histone
deacetylase inhibitors [like vorinostat and romidepsin,
which have already been approved by the Food and Drug
Administration for the treatment of cutaneous T-cell lym-
phoma (CTCL)12,13], also appeared on the list.
Furthermore, using the GSEA program we observed in
the PTCL molecular signature that the expression of
PIK3CD (the gene encoding p110δ) was the only PI3K iso-
form to be significantly correlated with several survival
pathways, such as the T-cell receptor, nuclear factor-κB and
CD40 pathways (Figure 1B). Moreover, we found that both
PIK3CD and PIK3CA (encoding p110a) were overex-
pressed in the six PTCL and CTCL cell lines (Figure 1C) and
in primary T cells isolated from five patients with Sézary’s
syndrome (Figure 1D), compared to the expression by nor-
mal T cells from healthy donors.
Since the PI3K pathway is frequently altered at the genet-
ic level in many types of human cancer, the mutational sta-
tus of several genes in the pathway was explored in six
PTCL and CTCL cell lines. We did not find any known
mutation in PIK3CA, AKT1, PTEN, KRAS and BRAF genes
in any cell line. The described14 NRAS mutation Q61K was
confirmed in the HuT78 cell line, but was absent from the
other PTCL cell lines (data not shown). Although no muta-
tions have yet been reported in the PIK3CD gene,15 two
described variants16 were also studied in PTCL cell lines. We
found that the SR786 cell line carried a single nucleotide
polymorphism (c935g → S312C, rs61755420) (data not
shown). Moreover, these PIK3CD polymorphisms were ana-
lyzed in a series of 27 PTCL cases. Interestingly, we
observed two cases (one angioimmunoblastic T cell lym-
phoma and one anaplastic large cell lymphoma ALK+) har-
boring the same polymorphism. Additionally, one case of
e. martín-sánchez et al.
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PTCL-not otherwise specified was found to have another
single nucleotide polymorphism in this region (c2319t →
S773S, rs139848768) (data not shown).
These data indicate that PI3Kδ is an attractive, potential
therapeutic target in PTCL.
Effects of genetic silencing of the delta and alpha 
isoforms of phosphatidylinositol-3-kinase on peripheral 
T-cell lymphoma cell lines
To test the hypothesis that targeting PI3Kδ is of therapeu-
tic value in PTCL, we performed genetic silencing experi-
ments to specifically abolish PIK3CD and PIK3CA expres-
sion (because gain-of-function mutations in PIK3CA occur
very frequently in human tumors6). The efficiency of the
silencing was 60-90% at the mRNA level, depending on the
cell line and the time point (Online Supplementary Figure S1).
We observed a slight tendency in MyLa and SR786 cell
lines, but not in HuT78, to undergo apoptosis when
PIK3CD (Figure 2A) or PIK3CA (Figure 2B) were knocked
down, although the differences compared with the non-
template control were not statistically significant in any
case. No significant changes in the cell cycle profile were
observed in any condition or cell line (data not shown). The
results suggest that the active protein remaining after
knockdown could maintain survival of PTCL cell lines.
Effects of specific pharmacological inhibition 
of phosphatidylinositol-3-kinase-delta on peripheral 
T-cell lymphoma survival
In order to inhibit the PI3Kδ catalytic activity more effi-
ciently, PTCL cell lines were treated with the specific phar-
macological PI3Kδ inhibitor CAL-101. We observed that
this drug generally reduced cell viability only at high doses
(Figure 2C). Accordingly, CAL-101 was not able to induce
apoptosis in any PTCL cell line, only HH suffered an 8%
increase in apoptosis compared to the DMSO-treated cells,
even when incubated with a dose of 10 μM for 72 h (Figure
2D). Similarly, slight cell cycle arrest at G0/G1 was found
after exposure to 5 μM CAL-101 for 24 h in HH and DERL7
cell lines (Figure 2E). These results confirmed that the inhi-
bition of PI3Kδ alone was not sufficient to reduce PTCL cell
survival, suggesting that different PI3K isoforms may share
redundant functions.
Effects of the pharmacological inhibition of all 
phosphatidylinositol-3-kinase isoforms on peripheral 
T-cell lymphoma survival
In order to inhibit all class I PI3K isoforms, six PTCL and
CTCL cell lines were treated with three pharmacological
PI3Ki (LY294002, ETP-45658 and GDC-0941). Although
these drugs have different specificities (LY294002 is a dual
PI3K inhibition in peripheral T-cell lymphomas
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Figure 1. PI3K is a potential therapeutic target in PTCL. (A) Connectivity Map identified PI3K/mTOR pathway inhibitors (indicated by arrows)
as the drugs that could potentially reverse (negative enrichment score) the PTCL molecular signature in a very significant manner. (B) The
GSEA program revealed that three survival pathways [T-cell receptor (TCR), NF-κB and CD40 signaling] were positively and significantly (false
discovery rate <0.25) correlated with PIK3CD expression in the PTCL molecular signature. (C and D) Both PIK3CA and PIK3CD genes were
overexpressed in (C) PTCL and CTCL cell lines and (D) Sézary’s syndrome (SS) primary T cells compared with normal T cells isolated from
healthy donors (control #1-3) measured by quantitative RT-PCR.
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puromycin 4 -0.943 <0.00001
geldanamycin 15 -0.599 <0.00001
LY-294002 61 -0.408 <0.00001
trichostatin A 182 -0.385 <0.00001
alvespimycin 12 -0.603 0.00006
MS-275 2 -0.989 0.00030
wortmannin 18 -0.479 0.00036
prochlorperazine 16 -0.465 0.00102
monorden 22 -0.392 0.00140
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PI3K/mTOR inhibitor and the other two are specific pan-
PI3Ki10,17), all of them had similar effects on PTCL cell line
survival (Online Supplementary Figure S2). We found that
GDC-0941 was able to reduce cell viability in all cell lines in
a dose-dependent manner, but the effect was stronger in
some cell lines than in others, such as HuT78 and MJ,
which were considered to be resistant (Figure 3A).
Furthermore, GDC-0941 promoted cell cycle arrest at the
G0/G1 phase in all PTCL cell lines, being stronger in sensi-
tive cells lines than in resistant ones (Figure 3B). These dif-
ferential responses were confirmed at the level of apoptosis
induction: only the sensitive cell lines underwent slight
apoptosis upon treatment with pan-PI3Ki (Figure 3C), while
the resistant cell lines HuT78 and MJ did not. These results
indicate that the pharmacological inhibition of all PI3K iso-
forms was more effective than isoform-specific inhibition.
Biomarkers for pan-phosphatidylinositol-3-kinase
inhibitors in peripheral T-cell lymphoma
In order to test the activity of the pan-PI3Ki in PTCL cell
lines, the phosphorylation status of several proteins belong-
ing to the PI3K pathway was examined following GDC-
0941 treatment. First, we found by flow cytometry that
AKT phosphorylation, the most direct target of PI3K,6 was
reduced overall in all cell lines after 4 h of treatment with
GDC-0941 (Figure 4A), confirming that the drug was
indeed inhibiting PI3K even in the resistant cell line HuT78,
although the reduction was not very substantial. Next, we
studied other downstream proteins and observed that
GSK3b and p70S6K phosphorylation was reduced in the
sensitive cell lines, but not in the resistant ones, even after
high-dose treatment with GDC-0941 (Figure 4B). These
data suggest that pGSK3b and p-p70S6K could act as bio-
markers for the response to PI3Ki in PTCL cell lines.
Cooperation between phosphatidylinositol-3-kinase and
ERK pathways in peripheral T-cell lymphoma
Although the pharmacological pan-PI3Ki strategy
seemed to be more effective than the isoform-specific
inhibitor approach, the effects were not very dramatic. In
order to determine whether another cellular pathway
could compensate for the reduced PI3K activity and sus-
e. martín-sánchez et al.
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Figure 2. Effects of a single PI3K isoform inhibition on PTCL and CTCL cell line survival. (A) PIK3CD knockdown by siRNA slightly, but not
significantly, increased induction of apoptosis in MyLa and SR786 cell lines, while no effects were observed in HuT78. * indicates a statisti-
cally significant difference (P<0.05). (B) A slight, but not significant, increase in apoptosis was found in MyLa and SR786, but not in HuT78,
when PIK3CA was knocked down. (C) The specific pharmacological PI3Kδ inhibitor CAL-101 was only able to reduce PTCL cell line viability
at high doses. (D) Most of the PTCL cell lines did not undergo apoptosis upon treatment with CAL-101. The Y axis indicates the percentage
of annexin V+/propidium iodide- plus annexin V+/propidium iodide+ cells in the treatment with 10 μM CAL-101 minus the cell death in DMSO.
(E) After exposure to 5 μM CAL-101 for 24 h most of the PTCL cell lines were not arrested in any cell cycle phase; only HH and DERL7 were
slightly arrested at G1.
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tain PTCL survival, we studied the phosphorylation status
of ERK, because the Ras/Raf/MEK/ERK pathway is one of
the most essential pathways in cell survival.18 Following
treatment with GDC-0941 for 24 h, strong ERK activation
was observed in the MyLa and SR786 cell lines, but not in
HuT78 (Figure 5A). This result could explain the marginal
effects on cell survival we had observed when PI3K was
pharmacologically or genetically inhibited. The differen-
tial behavior of HuT78 could be explained by its resistance
to PI3Ki: perhaps the ERK pathway did not need to be
activated in this cell line in the presence of GDC-0941,
because even under these conditions the downstream
members of PI3K were still activated, sustaining cell sur-
vival (Figure 4B). More importantly, these results could
support the use of a combined pan-PI3Ki + MEKi treat-
ment in PTCL.
PTCL and CTCL cell lines were, therefore, treated with
the pan-PI3Ki GDC-0941 plus the MEKi UO126 for 72 h.
We found that the combination was highly synergistic (CI
<1) in four of the six PTCL cell lines at doses equivalent to
IC50 values (Figure 5B). On the other hand, we observed a
slight antagonism (CI >1) in the HuT78 cell line. Moreover,
the combination enhanced the cell cycle arrest at G0/G1 in
all PTCL cell lines (Figure 5C). In contrast, overall, the drug
combination did not increase the apoptosis induced by
each drug alone (Online Supplementary Figure S3). This is
probably due to the levels of pAKT and pERK, which
remained even in the presence of the drug combination
(Online Supplementary Figure S4). Importantly, simultaneous
PI3K and MEK inhibition significantly reduced cell viability
in primary tumor T cells ex vivo; at higher doses, the drug
combination had a stronger effect than the pan-PI3Ki alone
(Figure 5D). 
These results suggest that combined treatment with pan-
PI3Ki + MEKi could be more effective than treatment with
a PI3Ki alone and that the combination could be of thera-
peutic value in the treatment of PTCL and CTCL.
Discussion
Here we hypothesized that PI3K inhibition, especially
inhibition of the delta isoform, could be of therapeutic
PI3K inhibition in peripheral T-cell lymphomas
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Figure 3. Effects of the pharmacological pan-PI3Ki GDC-0941 on PTCL and CTCL cell line survival. (A) GDC-0941 reduced PTCL cell viability
after 72 h treatment in all cell lines, but HuT78 and MJ cell lines were more resistant to the PI3Ki. (B) GDC-0941 promoted cell cycle arrest
at the G1 phase in all studied PTCL cell lines. The arrest was stronger in sensitive cell lines than in resistant ones. (C) GDC-0941 significantly
induced apoptosis in sensitive cell lines, but not in resistant ones. The Y axis indicates the percentage of annexin V+/propidium iodide- plus
annexin V+/propidium iodide+ cells following treatment with 1 μM GDC-0941 minus the cell death in DMSO. *Indicates a statistically sig-
nificant difference compared with DMSO (P<0.05).
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value in PTCL because: (i) our in silico approach identified
PI3K pathway inhibitors as drugs that potentially reverse
the PTCL molecular signature; (ii) PI3Kδ has been
described to play a role in the differentiation, survival and
activation of normal T cells, and so is probably also impor-
tant for T-cell transformation;19-21 (iii) PIK3CDwas the only
isoform to be significantly correlated with survival path-
ways in this PTCL signature; and (iv) we found that
PIK3CD was much more overexpressed than PIK3CA in
PTCL and CTCL cell lines and in Sézary’s syndrome pri-
mary T cells. 
However, our results indicated that the genetic or specif-
ic pharmacological inhibition of PI3Kδ had no effects on
the survival of PTCL cell lines. CAL-101 is a PI3Kδ inhibitor
that has been reported to have very promising preclinical
activity in chronic lymphocytic leukemia (either alone22,23
or in combination with other agents24) and very recently,
also in Hodgkin’s lymphoma.25 The initial clinical data in
phase I/II studies were most impressive in chronic lympho-
cytic leukemia, and have created some excitement about
PI3K drug development. Nevertheless, some controversy
exists: leukemia and lymphomas generally express all class
I PI3K isoforms and rarely carry mutations in PI3K genes or
have PTEN loss. In addition, the first set of preclinical stud-
ies with CAL-101 did not clearly predict the dramatic effi-
cacy of the drug in clinical trials: cytotoxic effects on
human chronic lymphocytic leukemia samples in vitrowere
generally achieved only at high CAL-101 doses (10 μM).
These results suggest that selective PI3Kδ inhibition has a
minimal impact on cell-intrinsic survival signals in B-lin-
eage cancer cells, where it seems to act mainly by perturb-
ing the signals received from the tumor microenviron-
ment.26,27
Moreover, even in cancers that seem to be specifically
reliant on either PI3Ka or b, there is the concern that other
non-targeted PI3K isoforms might eventually compensate
for the decreased activity of the targeted isoform.6 It has
been described that removal of more than 90% of p85-
associated PI3K activity (a, b and δ isoforms) did not com-
promise the proliferation in hematopoietic progenitor
cells.28 These data could explain the absence of effect that
we observed when a single PI3K isoform was inhibited in
PTCL cell lines, because our knockdown efficiency was
80% at the mRNA level, and thus, more than 10% of the
protein was still active, along with the other intact iso-
forms, allowing the survival of PTCL cell lines.
Accordingly, a stronger effect was found with the pan-
PI3Ki GDC-0941. All cell lines were arrested at the G0/G1
phase and a subset of them underwent apoptosis. Overall,
the response was mainly cytostatic, as widely reported.6,28,29
Almost complete class IA inhibition is required to produce
cell death, but such full inhibition of PI3K activity might be
difficult to achieve with ATP-competitive inhibitors. This
could partially explain why PI3Ki do not induce apoptosis
but rather cytostasis.28 However, this outcome could also
be explained by alternative mechanisms of activation of
downstream effectors through feedback loops,4 especially
because of the inconsistent reduction of pAKT we
observed after GDC-0941 treatment, which might also
suggest an AKT-independent mechanism of action. PI3K
pathway members are able to interact very actively with a
number of proteins, creating a very complex network.30
Cooperation between the PI3K/AKT and the
Ras/Raf/MEK/ERK pathways has been extensively
described in many types of cell types.6,28,31 Interestingly, we
found that ERK phosphorylation was increased upon PI3Ki
treatment in PTCL cell lines, probably as a part of a com-
pensatory up-regulation of interconnected pathways.
More importantly, the combination of PI3Ki + MEKi was
highly synergistic overall (as reported already6,28,31) in vivo
and ex vivo, enhancing the cytostatic effect although with-
out induction of apoptosis.
Unfortunately, the biological basis of the poor outcome in
patients with PTCL, in contrast to that of patients with
aggressive B-cell lymphomas, is not well understood.3
Biomarkers that predict the response to a given therapy are,
therefore, needed. Very recently, a study in primary PTCL
cases highlighted the clinical relevance of pAKT, which was
negatively correlated with the response rate and survival,32
thus supporting the use of PI3Ki in PTCL therapy. Here, we
present preclinical evidence suggesting that PI3Ki could be
potential therapeutic agents for the treatment of PTCL.
Furthermore, we found different sensitivities among the
PTCL cell lines and observed that phosphorylation of
GSK3b and p70S6K was only reduced in the most sensitive
cell lines, while remaining unchanged in the resistant cell
lines. This result suggests that these phospho-proteins
could act as potential pharmacodynamic biomarkers for the
response to PI3Ki in PTCL.
In addition, we looked for biomarkers that could distin-
guish potential responders before treatment, such as muta-
tions in some parts of the PI3K pathway. Although muta-
tions in PIK3CA, AKT1 and PTEN have been detected in
e. martín-sánchez et al.
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Figure 4. PI3Ki activity and response biomarkers in PTCL and CTCL
cell lines. (A) GDC-0941 diminished AKT phosphorylation in a dose-
dependent manner in all cell lines after 4 h of treatment. (B) GSK3b
and p70S6K phosphorylation was reduced only in sensitive cell lines
after 4 h exposure to GDC-0941, but not in resistant cell lines.
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patients with leukemia, these mutations appear to be rare in
hematologic neoplasms.4,33 None of the known activating
mutations in PIK3CA, AKT1, KRAS or BRAF or deletions in
PTEN was found in any PTCL and CTCL cell line.
Consistent with this, PTEN alterations were not observed
at the genetic or protein levels in a series of cases of PTCL-
not otherwise specified.34 The only gene variant found in
one of the six PTCL cell lines and two of the 27 PTCL cases
was PIK3CD, which harbored two single nucleotide poly-
morphisms (c935g = rs61755420 and c2319t =
rs139848768). The first polymorphism (c935g) might be
somehow related to the incidence of anaplastic large cell
lymphoma ALK+, because it was present in the only
anaplastic large cell lymphoma ALK+ cell line available and
in one of the three cases of anaplastic large cell lymphoma
ALK+. Nevertheless, a case-control study reporting a signif-
icant association in a large series would be required to
explore this possibility.
In conclusion, collectively these results suggest that the
simultaneous inhibition of all PI3K isoforms, instead of spe-
cific PI3Kδ inhibition, could be a therapeutic strategy in a
subset of PTCL and CTCL. More importantly, the cytosta-
tic effects can be enhanced in combination with MEKi, and
might improve the poor outcome in PTCL patients, who
lack efficient therapies.
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Figure 5. Cooperation between PI3K and ERK pathways in PTCL and CTCL in vitro and ex vivo. (A) ERK phosphorylation was increased in
MyLa and SR786 cell lines after 24 h of treatment with GDC-0941 10 μM. (B) The combination index (CI) was calculated for different doses
of the combined pan-PI3Ki (GDC-0941) + MEKi (UO126): CI <1 indicates synergism between the two drugs, CI ≈1 indicates an additive effect,
CI >1 indicates antagonism. (C) The combination enhanced cell cycle arrest at G1 in all PTCL cell lines when compared with single treat-
ments. (D) The PI3Ki + MEKi combination significantly reduced cell viability in primary tumor T cells from eight CTCL patients (5 with Sézary’s
syndrome and 3 with mycosis fungoides). *indicates statistically significant differences compared with DMSO (P<0.05).
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